Table 1 Patient characteristics
From: Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT
DME | nAMD | |
|---|---|---|
N | 78 | 156 |
Age in years at inclusion | mean (SD) | 63.5 (11.7) | 78.2 (8.3) |
Female gender | n (%) | 30 (38.5) | 95 (60.9) |
Newly treated patients | n (%) | 25 (32.1) | 53 (34.0) |
Experienced patients | n (%) | 50 (64.1) | 99 (63.4) |
Non-persistent patients | n (%) | 3 (3.8) | 4 (2.6) |
Time since first diagnosis of DME/nAMD in years | mean (SD) | 3.0 (3.1) | 2.9 (3.1) |
Both eyes affected | n (%) | 49 (62.8) | 52 (33.3) |
VA LogMAR at start of treatment—treated eye | mean (SD)a | 0.5 (0.2) | 0.4 (0.2) |
VA LogMAR at start of treatment—untreated eye | mean (SD)b | 0.5 (0.4) | 0.5 (0.3) |
Duration of treatment in years | mean (SD) | 1.9 (0.8) | 1.9 (0.9) |
Duration of treatment ≤ 12 months | n (%) | 14 (17.9) | 32 (20.5) |
Number of injections per treated eye since start of therapy | mean (SD) | 8.9 (5.5)c | 12.2 (9.0)d |
Catarakt | n (%) | 40 (51.3) | 53 (34.0) |
Glaucoma | n (%) | 8 (10.3) | 19 (12.2) |
Diabetic Retinopathy | n (%) | 63 (80.8) | 0 (0.0) |
Patient reading capabilities assessed by physicianse | ||
Without magnifying glass | n (%) | 39 (50%) | 110 (70.5%) |
With magnifying glass | n (%) | 4 (5.1%) | 16 (10.3%) |
Not able to read | n (%) | 0 (0%) | 7 (4.5%) |
Unknown | n (%) | 35 (44.9%) | 23 (14.7%) |
Patient reading capabilities assessed by patientsc | ||
Without magnifying glass | n (%) | 59 (75.6%) | 104 (66.7%) |
With magnifying glass | n (%) | 12 (15.4%) | 40 (25.6%) |
Not able to read | n (%) | 7 (9%) | 12 (7.7%) |
Unknown | n (%) | 0 (0%) | 0 (0%) |